Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Phase 1 clinical trial included five escalating dose cohorts of eight healthy volunteers each, that either received one intravenous dose of NMT-cP12 or a control (normal saline).
Lead Product(s): NMT-cP12
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NMT-cP12
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020